V+ Invests in AmVac AG

ZUG, Switzerland, December 3 - The Swiss biopharmaceuticals company AmVac AG in Zug has joined forces
with the long-term strategic investor V+ GmbH & Co Fonds 2 KG. The private
equity company based in Dresden has invested CHF 1,500,000 in AmVac AG since
the first half of 2009. Last week V+ GmbH & Co Fonds 2 KG announced their
intention of acquiring further shares in AmVac AG to the sum of CHF
3,000,000.00.

Michael Vogel, spokesman of the investment board: "We agree with boosting
the holding because our confidence in AmVac AG has continued to grow. The
extremely encouraging prospects described by AmVac for vaccines for the
indications premature babies and prostatitis have convinced us. The
experienced management team has also strengthened our trust. AmVac have
informed us that marketing authorisations for the two vaccines FemiVac and
ProstaVac are pending all over the world, and we are expecting a major return
on investment in the coming years."

Melinda-Kinga Karpati, CEO of AmVac AG: "In V+ we have found an
investment company that is going beyond their network to actively support us
in operative positioning. This gives us enormous drive to push on with our
projects full steam ahead." AmVac AG has also been able to convince other
renowned private investors such as Dr. Mo Ibrahim.

AmVac AG

AmVac AG is a biopharmaceutical company situated in Switzerland. The
company focuses on the vaccine market with its above-average growth figures.
There are two therapeutic vaccines in the pipeline which are soon to be
launched in the fields of gynaecology and urology. Further innovative
vaccines and technologies are at the development stage. The renowned market
research company Frost & Sullivan awarded AmVac AG the coveted prize
"Enabling Technology of the Year Award" in 2007.

V+ GmbH & Co Fonds 2 KG

V+ GmbH & Co Fonds 2 KG is one of the leading Venture Capital
funds that invests in direct shareholdings and secondary market holdings in
German-speaking countries.

    Contact:
    Ariane Meynert, Head of PR/IR; mail: meynert@amvac.ch ,
    Tel.: +41-41-725-3234, Cell: +41-79-79-334-19,
    Michael Vogel, V+: Mail: vogel@venture-plus.de .

Contact: Ariane Meynert, Head of PR/IR; mail: meynert at amvac.ch , Tel.: +41-41-725-3234, Cell: +41-79-79-334-19, Michael Vogel, V+: Mail: vogel at venture-plus.de .